Anesiva, Inc.

After numerous spectacular failures, investors and Big Pharma are pulling back from novel pain drug development, but they risk losing out on improving R&D in the field. By Marc Wortman Pain has been a

Anesiva is to file for bankruptcy protection after its proposed merger with Arcion Therapeutics, which appeared to be the struggling pharmaceutical company's saviour in August, was terminated. Anesiva

Acceleron Pharma, a privately held US biopharmaceutical company focused on the discovery, development, manufacture and commercialisation of biotherapeutics that modulate the growth of red blood cells,

Biopharmaceutical, medical device, and in vitro diagnostics start-up dealmaking from July through September 2009. Data from Elsevier's Strategic Transactions. Deanna F. Deinzer Financings In the third